Levobunolol for the long-term treatment of glaucoma.
Systemically, levobunolol is as effective as propranolol for cardiovascular indications, with a greater potency and greater duration of action. Ocularly, levobunolol is as effective and as safe as topical timolol for the long-term treatment of elevated IOP. The utility of topical levobunolol as an additional, effective beta-blocker for the treatment of glaucoma will be determined by additional research and use by ophthalmologists in countries where levobunolol is approved.
D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D002986:Clinical Trials as Topic; D005901:Glaucoma / Q000188:drug therapy*; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007700:Kinetics; D002040:Levobunolol / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D009420:Nervous System / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D013997:Time Factors
D011943:Receptors, Adrenergic, beta; D002040:Levobunolol